Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12778370 | 0.86 | THRA (0.49) | MAPTL3MBTL1KMT2APDK2ALDH1A1 | |
| SCHEMBL12778374 | 0.86 | PDK2 (0.43) | MAPTL3MBTL1KMT2APDK2ALDH1A1 | |
| SCHEMBL17688873 | 0.83 | NQO1 (0.48) | NQO1MAPTLMNAKMT2AKDM4E | |
| SCHEMBL14949902 | 0.81 | NQO1 (0.46) | NQO1ARMAPTL3MBTL1LMNA | |
| SCHEMBL6832255 | 0.81 | NQO1 (0.46) | NQO1ARMAPTL3MBTL1LMNA | |
| SCHEMBL8257891 | 0.81 | MAOA (0.39) | ARL3MBTL1KMT2AKDM4EALDH1A1 | |
| SCHEMBL12126640 | 0.80 | LMNA (0.52) | NQO1ARMAPTL3MBTL1LMNA | |
| SCHEMBL5953654 | 0.80 | MAPT (0.45) | NQO1ARMAPTL3MBTL1LMNA | |
| SCHEMBL30649163 | 0.80 | NQO1 (0.45) | NQO1ARMAPTL3MBTL1LMNA | |
| SCHEMBL12875593 | 0.80 | NQO1 (0.45) | NQO1ARMAPTL3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210002254-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-01-07 | — | — | US | disclosed |
| US-20160263234-A1 | PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2016-09-15 | — | — | US | disclosed |
| US-9315542-B2 | Prodrugs of peptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9309283-B2 | Prodrugs of peptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20140105921-A1 | Prodrugs of Peptide Epoxy Ketone Protease Inhibitors | ONYX THERAPEUTICS, INC. | 2014-04-17 | — | — | US | disclosed |
| WO-2011026024-A2 | IMIDAZO [4,5-D] PYRIDAZINE COMPOUNDS FOR TREATING VIRAL INFECTIONS | GLAXOSMITHKLINE LLC (US) | 2011-03-03 | — | — | WO | disclosed |
| US-20110053892-A1 | Imidazo[4,5-d]Pyridazine Compounds For Treating Viral Infections | LEIVERS MARTIN | 2011-03-03 | — | — | US | disclosed |
| US-20110053892-A1 | Imidazo[4,5-d]Pyridazine Compounds For Treating Viral Infections | LEIVERS MARTIN | 2011-03-03 | — | — | US | disclosed |
| US-20110052534-A1 | Imidazopyridazine Compounds for Treating Viral Infections | LEIVERS MARTIN | 2011-03-03 | — | — | US | disclosed |
| US-20110052534-A1 | Imidazopyridazine Compounds for Treating Viral Infections | LEIVERS MARTIN | 2011-03-03 | — | — | US | disclosed |
| WO-2011026091-A1 | IMIDAZOPYRIDAZINE COMPOUNDS FOR TREATING VIRAL INFECTIONS | GLAXOSMITHKLINE LLC (US) | 2011-03-03 | — | — | WO | disclosed |
| WO-2009111501-A1 | DERIVATIVES OF IMIDAZO [4, 5-D] PYRIDAZINE AND THEIR USE AS ANTI-VIRAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20090226398-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. | 2009-09-10 | — | — | US | disclosed |
| US-20090226398-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140105921-A1 | Prodrugs of Peptide Epoxy Ketone Protease Inhibitors | PREP, VIP, PEPD | NQO1 1981/4885AR 2258/4885MAPT 3880/4885 |
| US-20110052534-A1 | Imidazopyridazine Compounds for Treating Viral Infections | ACE, ACE2, TPMT | NQO1 1069/4885AR 4740/4885MAPT 1421/4885 |
| US-20160263234-A1 | PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, VIP, PEPD | NQO1 1981/4885AR 2258/4885MAPT 3880/4885 |
| US-20210002254-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | NQO1 2962/4885AR 413/4885MAPT 1929/4885 |
| US-20110053892-A1 | Imidazo[4,5-d]Pyridazine Compounds For Treating Viral Infections | MAVS, ZC3HAV1, IL5 | NQO1 1618/4885AR 4479/4885MAPT 1121/4885 |
| US-20090226398-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | MAVS, SARS1, HAVCR2 | NQO1 3277/4885AR 4786/4885MAPT 1163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.